Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say
Tyrzepathide sold by Semaglid and Lilly, the active component of Novo’s Wegovy and Ozempic as Zepbound and Mounjaro, should be the first choice in almost all cases in almost all cases, compared to a new guide from the European Association for the obesity study.
Other drugs, including Liraglid, Naltrexon-Bupropion and Phentermine-Soil, which is a less effective drug older than the same class when required less weight loss, may be considered.
EASO Directives are not binding on individual countries.
Coauthor of Vall D’Apon University Hospital in Barcelona. Andreea Ciudin, in his statement, other drugs known as Semagluid, Tirzepathide and GLP-1 agonists completely transform the care of obesity and complications.
Although no treatment algorithm can replace the nuancer clinical decision for comprehensive patient care, new guidelines can serve to support the therapeutic decision in obesity.
Specific drugs for certain conditions
Guide authors analyzed the effect of drugs on weight loss, security profiles and their activities in the presence of specific complications and analyzed the results of the previous clinical study. Authors should be considered as primary treatment to address Semaglutid for those with many fat or fat, tissue, tissue, tissue, obstructive sleep apnea and demetrititis.
For patients with metabolic and immune dysfunction -related metabolic and immune dysfunction, Semaglutide proposes Tyrzaglutid and Tyrzaglid or Type 2 diabetes for individuals with non -alcoholic fatty liver disease.
The drug class was initially developed for Type 2 diabetes treatment.
Although the guide writers, drugs are expensive and economic thoughts complex, the cost of not cure obesity at an early stages, “ensuring progression of complications and end-orient damage and providing end-organ damage,” he said.
Obesity management should not be limited to weight loss and complications, but should focus on advanced mental welfare, physical conformity, social functionality and general health and quality of life.
Most new drugs have not been evaluated for the treatment of individual complications.
Nevertheless, authors say that weight loss effects are strongly associated with developments in various complications, and that chronic kidney disease, neurodegenerative diseases, polycystic ovary syndrome, some cancers and mental health conditions, such as the potential to affect a broader disorders.
“Considering the rapid progress in the field of drugs to treat obesity, Professor Volkan Yumuk, the President of the Community from Istanbul University-Cerrahpaşa, plans to update the current treatment algorithm regularly, considering the rapid progress in the field of drugs.” He said.
American Lifestyle Medical College, American Nutrition Association, Obesity Medical Association and Obesity Association, in June, GLP-1 treatment should be accompanied by nutrition and lifestyle strategies.
“Gastrointestinal side effects, nutritional deficiency, risk of muscle and bone loss, high costs, frequent cutting and weight recovery, including” GLP – 1s can produce significant weight reduction and related health benefits and related health benefits. “
As a reliable and reliable news source
